Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Hospital Acquired Pneumonia (HAP) Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Hospital Acquired Pneumonia (HAP) Overview | 10 | 1 |
| Pipeline Products for Hospital Acquired Pneumonia (HAP) Comparative Analysis | 11 | 1 |
| Hospital Acquired Pneumonia (HAP) Therapeutics under Development by Companies | 12 | 2 |
| Hospital Acquired Pneumonia (HAP) Therapeutics under Investigation by Universities/Institutes | 14 | 1 |
| Hospital Acquired Pneumonia (HAP) Pipeline Products Glance | 15 | 4 |
| Late Stage Products | 15 | 1 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Unknown Stage Products | 18 | 1 |
| Hospital Acquired Pneumonia (HAP) Products under Development by Companies | 19 | 3 |
| Hospital Acquired Pneumonia (HAP) Products under Investigation by Universities/Institutes | 22 | 1 |
| Hospital Acquired Pneumonia (HAP) Companies Involved in Therapeutics Development | 23 | 18 |
| Achaogen Inc. | 23 | 1 |
| Adenium Biotech ApS | 24 | 1 |
| Aridis Pharmaceuticals LLC | 25 | 1 |
| AstraZeneca Plc | 26 | 1 |
| Bayer AG | 27 | 1 |
| Cardeas Pharma Corp. | 28 | 1 |
| MedImmune, LLC | 29 | 1 |
| Meiji Seika Pharma Co., Ltd. | 30 | 1 |
| Melinta Therapeutics, Inc | 31 | 1 |
| Merck &Co., Inc. | 32 | 1 |
| Motif Bio Plc | 33 | 1 |
| Nabriva Therapeutics AG | 34 | 1 |
| Savara Inc. | 35 | 1 |
| Sealife PHARMA GMBH | 36 | 1 |
| Shionogi &Co., Ltd. | 37 | 1 |
| Tetraphase Pharmaceuticals Inc. | 38 | 1 |
| Wockhardt Limited | 39 | 1 |
| Zavante Therapeutics, Inc. | 40 | 1 |
| Hospital Acquired Pneumonia (HAP) Therapeutics Assessment | 41 | 10 |
| Assessment by Monotherapy Products | 41 | 1 |
| Assessment by Combination Products | 42 | 1 |
| Assessment by Target | 43 | 2 |
| Assessment by Mechanism of Action | 45 | 2 |
| Assessment by Route of Administration | 47 | 2 |
| Assessment by Molecule Type | 49 | 2 |
| Drug Profiles | 51 | 69 |
| (amikacin sulfate + fosfomycin) Drug Profile | 51 | 2 |
| (avibactam + ceftazidime) Drug Profile | 53 | 4 |
| (ceftolozane sulfate + tazobactam sodium) Drug Profile | 57 | 5 |
| (cilastatin sodium + imipenem + relebactam) Drug Profile | 62 | 1 |
| (Pseudomonas + ventilator associated pneumonia) vaccine Drug Profile | 63 | 1 |
| AA-139 Drug Profile | 64 | 1 |
| Aerucin Drug Profile | 65 | 1 |
| amikacin sulfate Drug Profile | 66 | 2 |
| arbekacin Drug Profile | 68 | 1 |
| cefepime + zidebactam Drug Profile | 69 | 1 |
| delafloxacin Drug Profile | 70 | 8 |
| eravacycline Drug Profile | 78 | 6 |
| fosfomycin tromethamine Drug Profile | 84 | 2 |
| iclaprim mesylate Drug Profile | 86 | 3 |
| lefamulin acetate Drug Profile | 89 | 3 |
| MEDI-3902 Drug Profile | 92 | 1 |
| MEDI-4893 Drug Profile | 93 | 1 |
| Nu-2 Drug Profile | 94 | 1 |
| PAC-I Drug Profile | 95 | 1 |
| Panaecin Drug Profile | 96 | 1 |
| panobacumab Drug Profile | 97 | 1 |
| plazomicin sulfate Drug Profile | 98 | 4 |
| Qn-2251 Drug Profile | 102 | 1 |
| S-649266 Drug Profile | 103 | 2 |
| SLP-0905 Drug Profile | 105 | 1 |
| tedizolid phosphate Drug Profile | 106 | 7 |
| tosatoxumab Drug Profile | 113 | 2 |
| vancomycin hydrochloride Drug Profile | 115 | 3 |
| WCK-2349 Drug Profile | 118 | 1 |
| WCK-771 Drug Profile | 119 | 1 |
| Hospital Acquired Pneumonia (HAP) Dormant Projects | 120 | 1 |
| Hospital Acquired Pneumonia (HAP) Discontinued Products | 121 | 1 |
| Hospital Acquired Pneumonia (HAP) Product Development Milestones | 122 | 8 |
| Featured News &Press Releases | 122 | 1 |
| Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections | 122 | 1 |
| Jun 20, 2016: Results of Phase 2 Study of Merck's Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe | 122 | 1 |
| Feb 24, 2016: Aridis Pharmaceuticals Expands Patent Portfolio for Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets | 123 | 1 |
| Jan 07, 2016: Aridis Pharmaceuticals Reports Positive Phase 1 Clinical Results for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia | 124 | 1 |
| Dec 15, 2015: Iclaprim Clinical Trial Supplies Manufactured | 124 | 1 |
| Oct 13, 2015: Motif Bio Announces Results of Two Posters on Iclaprim at ID Week 2015 | 124 | 1 |
| Sep 29, 2015: Motif Announces Presentation of Two Posters on Iclaprim at ID Week 2015 | 125 | 1 |
| Jun 30, 2015: Aridis Pharmaceuticals Receives FDA Fast Track Designation for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia | 126 | 1 |
| Jan 08, 2015: Achaogen Announces Plazomicin Granted QIDP Designation by FDA | 127 | 1 |
| Oct 03, 2013: Tetraphase to Present New Data at IDWeek on Eravacycline s Potential Activity in Treating Serious Respiratory Infections | 127 | 1 |
| Sep 06, 2013: Trius Therapeutics to Present Data From Antibiotics Development Programs at ICAAC 2013 | 128 | 2 |
| Appendix | 130 | 2 |
| Methodology | 130 | 1 |
| Coverage | 130 | 1 |
| Secondary Research | 130 | 1 |
| Primary Research | 130 | 1 |
| Expert Panel Validation | 130 | 1 |
| Contact Us | 130 | 1 |
| Disclaimer | 131 | 1 |